ID: ALA2147921

Max Phase: Preclinical

Molecular Formula: C25H24ClF3N2O2

Molecular Weight: 440.47

Molecule Type: Small molecule

Representations

Canonical SMILES:  CN1CC[C@]23Cc4nc5ccc(C(F)(F)F)cc5cc4C[C@@]2(O)[C@H]1Cc1ccc(O)cc13.Cl

Standard InChI:  InChI=1S/C25H23F3N2O2.ClH/c1-30-7-6-23-13-21-16(8-15-9-17(25(26,27)28)3-5-20(15)29-21)12-24(23,32)22(30)10-14-2-4-18(31)11-19(14)23;/h2-5,8-9,11,22,31-32H,6-7,10,12-13H2,1H3;1H/t22-,23-,24-;/m1./s1

Standard InChI Key:  WFSPNMHYOYCKEW-AKEJJZJZSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 440.47

Molecular Weight (Monoisotopic): 440.1712

AlogP: 3.99

#Rotatable Bonds: 0

Polar Surface Area: 56.59

Molecular Species: NEUTRAL

HBA: 4

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 10.20

CX Basic pKa: 8.04

CX LogP: 4.09

CX LogD: 3.35

Aromatic Rings: 3

Heavy Atoms: 32

QED Weighted: 0.56

Np Likeness Score: 0.45

References

1. Ida Y, Matsubara A, Nemoto T, Saito M, Hirayama S, Fujii H, Nagase H..  (2012)  Synthesis of quinolinomorphinan derivatives as highly selective δ opioid receptor ligands.,  20  (19): [PMID:22967810] [10.1016/j.bmc.2012.08.004]

Source

Source(1):

• Scientific Literature